Patents by Inventor Sabine Hoves

Sabine Hoves has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method of treating cancer in a patient by administering an antibody which binds colony stimulating factor-1 receptor (CSF-1R)
    Patent number: 11542335
    Abstract: The current invention relates to the intermittent dosing of an anti-CSF-1R antibody in combination with macrophage activating agent, corresponding pharmaceutical compositions or medicaments using such combination therapy.
    Type: Grant
    Filed: February 25, 2019
    Date of Patent: January 3, 2023
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Sabine Hoves, Chia-Huey Ooi, Carola Ries, Solange Romagnoli, Dominik Ruettinger, Hadassah Sumum Sade
  • Methods for treating colon cancer or inhibiting cell proliferation by administering a combination of antibodies against human CSF-1R and antibodies against human PD-L1
    Patent number: 11512133
    Abstract: The present invention relates to the combination therapy of specific antibodies which bind human CSF-1R with specific antibodies which bind human PD-L1.
    Type: Grant
    Filed: February 6, 2020
    Date of Patent: November 29, 2022
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Frank Herting, Sabine Hoves, Carola Ries, Katharina Wartha
  • ANTI-HLA-G ANTIBODIES AND USE THEREOF
    Publication number: 20210147553
    Abstract: The present invention relates to anti-HLA-G antibodies and methods of using the same.
    Type: Application
    Filed: October 16, 2020
    Publication date: May 20, 2021
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Stefan DENGL, Sebastian FENN, Jens FISCHER, Andreas HINZ, Claudia KIRSTENPFAD, Stefan KLOSTERMANN, Joerg MOELLEKEN, Georg TIEFENTHALER, Sabine HOVES, Alexander BUJOTZEK, Meher MAJETY
  • COMBINATION THERAPY OF ANTIBODIES AGAINST HUMAN CSF-1R AND ANTIBODIES AGAINST HUMAN PD-L1
    Publication number: 20200392234
    Abstract: The present invention relates to the combination therapy of specific antibodies which bind human CSF-1R with specific antibodies which bind human PD-L1.
    Type: Application
    Filed: February 6, 2020
    Publication date: December 17, 2020
    Applicant: HOFFMANN-LA ROCHE INC.
    Inventors: Frank HERTING, Sabine HOVES, Carola RIES, Katharina WARTHA
  • 7-SUBSTITUTED SULFONIMIDOYLPURINONE COMPOUNDS AND DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF LIVER CANCER
    Publication number: 20200268762
    Abstract: The present invention relates to compounds of formula (I), wherein R1, R2 and R3 are as described herein, and their prodrugs or pharmaceutically acceptable salt, enantiomer or diastereomer thereof, for (use in) the treatment and/or prophylaxis of liver cancer.
    Type: Application
    Filed: February 26, 2019
    Publication date: August 27, 2020
    Applicant: Hoffmann-La Roche Inc.
    Inventors: THOMAS POESCHINGER, CAROLA RIES, HONG SHEN, HONGYING YUN, SABINE HOVES, CARINA HAGE
  • Sulfinylphenyl or sulfonimidoylphenyl benzazepines
    Patent number: 10428027
    Abstract: This invention relates to novel sulfinylphenyl or sulfonimidoylphenyl benzazepine compounds of the formula wherein X and R1 to R6 are as defined in the description and in the claims, as well as pharmaceutically acceptable salts thereof. These compounds are TLR agonists and may therefore be useful as medicaments for the treatment of diseases such as cancer, autoimmune diseases, inflammation, sepsis, allergy, asthma, graft rejection, graft-versus-host disease, immunodeficiencies, and infectious diseases.
    Type: Grant
    Filed: March 8, 2018
    Date of Patent: October 1, 2019
    Assignee: Hoffmann La-Roche Inc.
    Inventors: Sabine Hoves, Lisha Wang, Hongying Yun, Weixing Zhang, Wei Zhu
  • Intermittent dosing of an anti-CSF-1R antibody in combination with macrophage activating agent
    Publication number: 20190284284
    Abstract: The current invention relates to the intermittent dosing of an anti-CSF-1R antibody in combination with macrophage activating agent, corresponding pharmaceutical compositions or medicaments using such combination therapy.
    Type: Application
    Filed: February 25, 2019
    Publication date: September 19, 2019
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Sabine HOVES, Chia-Huey OOI, Carola RIES, Solange ROMAGNOLI, Dominik RUETTINGER, Hadassah Sumum SADE
  • COMBINATION THERAPY OF ANTIBODIES AGAINST HUMAN CSF-1R AND ANTIBODIES AGAINST HUMAN PD-L1
    Publication number: 20180346581
    Abstract: The present invention relates to the combination therapy of specific antibodies which human CSF-1R with specific antibodies which bind human PD-L1.
    Type: Application
    Filed: April 19, 2018
    Publication date: December 6, 2018
    Applicant: HOFFMANN-LA ROCHE INC.
    Inventors: Frank HERTING, Sabine HOVES, Carola RIES, Katharina WARTHA
  • GENERATION OF HUMAN MACROPHAGES IN IMMUNODEFICIENT NON-HUMAN HOSTS
    Publication number: 20180273628
    Abstract: The invention relates to the use of non-anti-human antibodies to stimulate the generation of human macrophages in immunodeficient non-human hosts, reconstituted with human immune system. According methods for the generation and host models with human xenografts as well as their use for cancer immunotherapy evaluation are also included.
    Type: Application
    Filed: May 29, 2018
    Publication date: September 27, 2018
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Jan ECKMANN, Sabine HOVES, Carola RIES
  • Sulfinylphenyl or Sulfonimidoylphenyl Benzazepines
    Publication number: 20180194735
    Abstract: This invention relates to novel sulfinylphenyl or sulfonimidoylphenyl benzazepine compounds of the formula wherein X and R1 to R6 are as defined in the description and in the claims, as well as pharmaceutically acceptable salts thereof. These compounds are TLR agonists and may therefore be useful as medicaments for the treatment of diseases such as cancer, autoimmune diseases, inflammation, sepsis, allergy, asthma, graft rejection, graft-versus-host disease, immunodeficiencies, and infectious diseases.
    Type: Application
    Filed: March 8, 2018
    Publication date: July 12, 2018
    Applicant: Hoffmann La-Roche Inc.
    Inventors: Sabine Hoves, Lisha Wang, Hongying Yun, Weixing Zhang, Wei Zhu
  • Benzazepine sulfonamide compounds
    Patent number: 9890124
    Abstract: This invention relates to novel benzazepine sulfonamide compounds of the formula wherein R4 or R5 is —SO2—NR7R8 and R1 to R8 and Y are as defined in the description and in the claims, as well as pharmaceutically acceptable salts thereof. These compounds are TLR agonists and may therefore be useful as medicaments for the treatment of diseases such as cancer, autoimmune diseases, inflammation, sepsis, allergy, asthma, graft rejection, graft-versus-host disease, immunodeficiencies, and infectious diseases.
    Type: Grant
    Filed: June 14, 2017
    Date of Patent: February 13, 2018
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Sabine Hoves, Matthias Koerner, Lisha Wang, Hongying Yun, Wei Zhu, Weixing Zhang
  • Benzazepine dicarboxamide compounds
    Patent number: 9822065
    Abstract: This invention relates to novel benzazepine dicarboxamide compounds of the formula wherein R1 to R4 are as defined in the description and in the claims, as well as pharmaceutically acceptable salts thereof. These compounds are TLR agonists and may therefore be useful as medicaments for the treatment of diseases such as cancer, autoimmune diseases, inflammation, sepsis, allergy, asthma, graft rejection, graft-versus-host disease, immunodeficiencies, and infectious diseases.
    Type: Grant
    Filed: February 14, 2017
    Date of Patent: November 21, 2017
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Sabine Hoves, Lisha Wang, Hongying Yun, Weixing Zhang, Wei Zhu
  • BENZAZEPINE SULFONAMIDE COMPOUNDS
    Publication number: 20170275253
    Abstract: This invention relates to novel benzazepine sulfonamide compounds of the formula wherein R4 or R5 is —SO2—NR7R8 and R1 to R8 and Y are as defined in the description and in the claims, as well as pharmaceutically acceptable salts thereof. These compounds are TLR agonists and may therefore be useful as medicaments for the treatment of diseases such as cancer, autoimmune diseases, inflammation, sepsis, allergy, asthma, graft rejection, graft-versus-host disease, immunodeficiencies, and infectious diseases.
    Type: Application
    Filed: June 14, 2017
    Publication date: September 28, 2017
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Sabine Hoves, Matthias Koerner, Lisha Wang, Hongying Yun, Wei Zhu, Weixing Zhang
  • Benzazepine dicarboxamide compounds
    Patent number: 9597333
    Abstract: This invention relates to novel benzazepine dicarboxamide compounds of the formula wherein R1 to R4 are as defined in the description and in the claims, as well as pharmaceutically acceptable salts thereof. These compounds are TLR agonists and may therefore be useful as medicaments for the treatment of diseases such as cancer, autoimmune diseases, inflammation, sepsis, allergy, asthma, graft rejection, graft-versus-host disease, immunodeficiencies, and infectious diseases.
    Type: Grant
    Filed: September 28, 2016
    Date of Patent: March 21, 2017
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Sabine Hoves, Lisha Wang, Hongying Yun, Weixing Zhang, Wei Zhu
  • COMBINATION THERAPY OF ANTIBODIES AGAINST HUMAN CSF-1R AND ANTIBODIES AGAINST HUMAN PD-L1
    Publication number: 20170051065
    Abstract: The present invention relates to the combination therapy of specific antibodies which bind human CSF-1R with specific antibodies which bind human PD-L1.
    Type: Application
    Filed: July 29, 2016
    Publication date: February 23, 2017
    Applicant: HOFFMANN-LA ROCHE INC.
    Inventors: Frank HERTING, Sabine HOVES, Carola RIES, Katharina WARTHA
  • Benzazepine Dicarboxamide Compounds
    Publication number: 20170014423
    Abstract: This invention relates to novel benzazepine dicarboxamide compounds of the formula wherein R1 to R4 are as defined in the description and in the claims, as well as pharmaceutically acceptable salts thereof. These compounds are TLR agonists and may therefore be useful as medicaments for the treatment of diseases such as cancer, autoimmune diseases, inflammation, sepsis, allergy, asthma, graft rejection, graft-versus-host disease, immunodeficiencies, and infectious diseases.
    Type: Application
    Filed: September 28, 2016
    Publication date: January 19, 2017
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Sabine Hoves, Lisha Wang, Hongying Yun, Weixing Zhang, Wei Zhu
  • Benzazepine dicarboxamide compounds
    Patent number: 9475775
    Abstract: This invention relates to novel benzazepine dicarboxamide compounds of the formula wherein R1 to R4 are as defined in the description and in the claims, as well as pharmaceutically acceptable salts thereof. These compounds are TLR agonists and may therefore be useful as medicaments for the treatment of diseases such as cancer, autoimmune diseases, inflammation, sepsis, allergy, asthma, graft rejection, graft-versus-host disease, immunodeficiencies, and infectious diseases.
    Type: Grant
    Filed: March 4, 2016
    Date of Patent: October 25, 2016
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Sabine Hoves, Lisha Wang, Hongying Yun, Weixing Zhang, Wei Zhu
  • 4-amino-imidazoquinoline compounds
    Patent number: 9447097
    Abstract: This invention relates to novel 4-amino-imidazoquinoline compounds of the formula wherein R1 to R4 are as defined in the description and in the claims, as well as pharmaceutically acceptable salts thereof. These compounds are TLR agonists and may therefore be useful as medicaments for the treatment of diseases such as cancer or infectious diseases.
    Type: Grant
    Filed: April 7, 2016
    Date of Patent: September 20, 2016
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Sabine Hoves, Bernd Kuhn, Fabienne Ricklin, Stephan Roever
  • Benzazepine Dicarboxamide Compounds
    Publication number: 20160257653
    Abstract: This invention relates to novel benzazepine dicarboxamide compounds of the formula wherein R1 to R4 are as defined in the description and in the claims, as well as pharmaceutically acceptable salts thereof. These compounds are TLR agonists and may therefore be useful as medicaments for the treatment of diseases such as cancer, autoimmune diseases, inflammation, sepsis, allergy, asthma, graft rejection, graft-versus-host disease, immunodeficiencies, and infectious diseases.
    Type: Application
    Filed: March 4, 2016
    Publication date: September 8, 2016
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Sabine Hoves, Lisha Wang, Hongying Yun, Weixing Zhang, Wei Zhu
  • 4-AMINO-IMIDAZOQUINOLINE COMPOUNDS
    Publication number: 20160222010
    Abstract: This invention relates to novel 4-amino-imidazoquinoline compounds of the formula wherein R1 to R4 are as defined in the description and in the claims, as well as pharmaceutically acceptable salts thereof. These compounds are TLR agonists and may therefore be useful as medicaments for the treatment of diseases such as cancer or infectious diseases.
    Type: Application
    Filed: April 7, 2016
    Publication date: August 4, 2016
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Sabine Hoves, Bernd Kuhn, Fabienne Ricklin, Stephan Roever